title: Two faces of ET: CALR and JAK2.
abstract: In this issue of Blood, Rumi et al and Rotunno et al demonstrate that essential thrombocythemia (ET) patients with calreticulin mutations exhibit lower leukocyte and hemoglobin values, higher platelet counts, and a lower thrombosis risk vs JAK2-mutated ET. Calreticulin-mutated ET appears to be a distinct entity with a more indolent course.
authors.affiliation: INSTITUTE FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE;
authors.forename: Mark P
authors.initials: MP
authors.lastname: Chao
authors.forename: Jason
authors.initials: J
authors.lastname: Gotlib
mesh_terms: D037282:Calreticulin / Q000235:genetics*; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D008297:Male; D009154:Mutation; D013920:Thrombocythemia, Essential / Q000175:diagnosis* / Q000235:genetics*
chemical_list: D037282:Calreticulin; D053614:Janus Kinase 2